Anlon Healthcare is seeking shareholder approval at its upcoming Annual General Meeting to acquire controlling stakes in two pharmaceutical entities through a significant share swap transaction. The company aims to acquire a 44.94% shareholding in Apiqo Organics Private Limited (AOPL) and a 47.41% shareholding in Bizotic Lifescience Private Limited (BLPL), which will result in both becoming wholly owned subsidiaries upon completion.

The acquisition involves the preferential allotment of up to 8,58,83,617 fully paid-up equity shares of face value ₹2 each. These shares will be issued at a price of ₹17.85 per share, including a security premium of ₹15.85. The total consideration for the AOPL acquisition is valued at ₹1,165,179,600, while the BLPL acquisition carries a total purchase consideration of ₹367,840,000.

Transaction Structure

The swap ratio and share allotment details are structured as follows:

The floor price for the issue was determined as ₹17.78 per equity share, based on the volume-weighted average price on the National Stock Exchange during the 90 trading days preceding August 6, 2026. An independent valuer, CA Gaurang Agarwal, confirmed this fair value in a report dated August 6, 2026.

Strategic Rationale

The company stated that full ownership of AOPL and BLPL will provide greater flexibility in implementing business strategies, allocating resources, and undertaking future expansion initiatives. The move is expected to strengthen Anlon Healthcare’s position in the healthcare and pharmaceutical sector by consolidating financial performance and operations. The transactions are classified as material related-party transactions under SEBI Listing Regulations, requiring prior shareholder approval.

Other Agenda Items

The AGM, scheduled for September 5, 2026, at 11:00 am via video conference, includes several other resolutions:

• Director Appointments: Reappointment of Punitkumar Rameshbhai Rasadia, who retires by rotation, and appointment of Kishan Vinodkumar Raja as an Independent Director.
• Capital Increase: Enhancement of authorized share capital from ₹110 crore to ₹130 crore by creating 10 crore additional equity shares.
• Related Party Transactions: Approval for future transactions with AOPL up to ₹80 crore and with BLPL up to ₹60 crore during FY27, primarily for the sale and purchase of goods.
• Cost Auditor: Ratification of remuneration for M/s M. C. Bambhroliya & Associates as Cost Auditor for FY27.

What the Numbers Show

The proposed share swap represents a substantial consolidation strategy without immediate cash outflow. By issuing new equity worth ₹1,533 crore (combined consideration) to existing shareholders of the target entities, Anlon Healthcare is leveraging its listed status to absorb unlisted or partially held assets. The issuance price of ₹17.85 is marginally higher than the regulatory floor price of ₹17.78, indicating minimal premium over the mandated minimum, which suggests a negotiated settlement focused on compliance rather than market premium capture for the selling shareholders.

Anlon Healthcare has revised its acquisition stakes for two pharmaceutical intermediates and active pharmaceutical ingredients (API) entities, correcting an inadvertent error in its initial August 8, 2026 disclosure. On August 13, 2026, the company clarified that it will acquire up to 44.94% stake in Apiqo Organics Private Limited (AOPL) and up to 47.41% stake in Bizotic Lifescience Private Limited (BLPL), replacing the previously reported figures of 32.52% and 43.33% respectively.

The transactions, valued at approximately ₹116.52 crore and ₹36.78 crore respectively, will continue to be settled through the preferential allotment of Anlon Healthcare’s equity shares. This share-swap structure preserves cash reserves while securing strategic supply chain synergies. All other terms, including the aggregate consideration and exchange ratios, remain unchanged from the initial intimation.

Deal Structure and Consideration

The consideration for both acquisitions will be discharged via share swaps at predetermined exchange ratios, with no cash outflow expected from Anlon Healthcare. For Apiqo Organics, the company will issue up to 45,16,200 equity shares at a price of ₹258 each. For Bizotic Lifescience, it will issue up to 22,99,000 equity shares at ₹160 each.

In total, Anlon Healthcare proposes to issue up to 8,58,83,617 equity shares with a face value of ₹2 each. The share exchange ratio is set at [1:14.45] for AOPL shareholders and [1:8.96] for BLPL shareholders. Any fractional entitlements will be rounded off to the nearest whole equity share.

Target Company Profiles

Apiqo Organics Private Limited, incorporated on December 1, 2025, manufactures pharmaceutical intermediates, industrial, fine, and inorganic chemicals. Its turnover surged from ₹977.78 lakh in FY24-25 to ₹7,254.11 lakh in FY25-26, indicating rapid scaling. Bizotic Lifescience Private Limited, incorporated in April 2015, specializes in manufacturing and exporting pharmaceutical drugs, APIs, and providing contract research and manufacturing services. Its turnover grew from ₹380.39 lakh in FY23-24 to ₹3,126.64 lakh in FY25-26.

Timeline and Regulatory Approvals

Both acquisitions are subject to customary closing conditions and shareholder acceptance of the share swap proposals. The company expects to complete the acquisitions within 90 days from the signing date or as mutually agreed. Listing and trading approvals from stock exchanges are required for the preferential issue of shares. The disclosures were made pursuant to Regulation 30 read with Part-A of Schedule III of the SEBI Listing Regulations and SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

What the Numbers Show

The correction highlights a more significant consolidation of control by Anlon Healthcare in its target entities than initially disclosed. By acquiring nearly 45% and 47% stakes respectively, the company moves closer to majority influence in both API manufacturers, strengthening vertical integration within the pharma supply chain. While the total financial outlay remains constant at approximately ₹1,533 crore, the higher stake percentages imply that the valuation per share of the target companies may have been adjusted downward or that the initial percentage calculation was based on a different share capital base. Promoters Punitkumar Rameshbhai Rasadia and Meet Atulkumar Vachhani will see their holdings increase from 18,59,20,000 and 9,40,80,000 shares to approximately 20,43,39,402 and 10,34,31,099 shares respectively, assuming full acceptance by all target company shareholders.